期刊
JOURNAL OF PERSONALIZED MEDICINE
卷 12, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/jpm12081334
关键词
dendrimers; clinical trials; phases 1, 2, and 3; polylysine; polyamidoamine
资金
- CNRS
This review focuses on the clinical trials conducted with dendrimers, assessing their safety and efficacy. It highlights the poor clinical translation of dendrimers thus far.
Dendrimers are highly branched macromolecules tailorable at will to fulfil precise requirements. They have generated a great many expectations and a huge number of publications and patents in relation to medicine, including in relation to personalized medicine, but have resulted in very poor clinical translation up to now. As clinical trials are the first steps in view of developing new compounds for (a personalized) medicine, this review focusses on the clinical trials carried out with dendrimers. Many of these clinical trials have been recently posted (2020-2022); thus, only very few concern phase 3. The safety and efficiency of essentially two main types of dendrimers, based on polylysine and polyamidoamide scaffolds, have been assessed up to now. These dendrimers were tested with the aim of treating mainly bacterial vaginosis, cancers, and COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据